(Q36805312)

16 August 2017

1 reference

title

Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back (English)

1 reference

16 August 2017

1 reference

1 reference

1

Monica M Bertagnolli

1 reference

16 August 2017

publication date

1 May 2007

1 reference

Lancet Oncology Commission

16 August 2017

published in

1 reference

16 August 2017

volume

8

1 reference

16 August 2017

issue

5

1 reference

16 August 2017

page(s)

439-443

1 reference

A Case–Control Study of Screening Sigmoidoscopy and Mortality from Colorectal Cancer

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970139-0

7 January 2021

Prostaglandins and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970139-0

7 January 2021

Cyclooxygenase 2 inhibitors: discovery, selectivity and the future

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970139-0

7 January 2021

The role of cyclooxygenase inhibitors in cancer prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970139-0

7 January 2021

Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970139-0

7 January 2021

Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970139-0

7 January 2021

Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970139-0

7 January 2021

Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970139-0

7 January 2021

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970139-0

7 January 2021

Celecoxib for the prevention of sporadic colorectal adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970139-0

7 January 2021

Celecoxib for the prevention of colorectal adenomatous polyps

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970139-0

7 January 2021

A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970139-0

7 January 2021

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970139-0

7 January 2021

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970139-0

7 January 2021

Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970139-0

7 January 2021

10.1016/S1470-2045(07)70139-0

Identifiers

DOI

1 reference

16 August 2017

1 reference